Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. - Wikidata - wikimedia - TriplyDB

Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

http://www.wikidata.org/entity/Q38592404

about

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics.Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report.Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy

P2860

Q38744570-074CC3CE-6235-4744-ABD3-A6D7E00E808F Q38851847-6A2E2DD6-4048-4C22-8E71-268A879EAB6A Q39073819-9DB9A0C6-F5F4-44BD-8DE3-C0026FDABC9D Q41283940-857F2F14-59C6-492D-B5AC-BD0A36CE3087 Q47574118-7E21451D-A894-4380-B96D-787900F172DA Q47581504-9A88BB1A-F374-482B-A758-0C8ADAF4949A Q51731261-AA7CF75F-A871-4A84-865D-854DEB3FB73F Q55479393-6EB6B48D-DB74-415E-8570-161C69D00EC8 Q58803803-BDC1F857-1F60-4107-9D04-BBB64339E90D

P2860

Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

http://www.wikidata.org/entity/Q38592404

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical benefits and impact o ...... ipsychotics for schizophrenia.

@en

type

label

Clinical benefits and impact o ...... ipsychotics for schizophrenia.

@en

prefLabel

Clinical benefits and impact o ...... ipsychotics for schizophrenia.

@en

P1433

Q38592404-DD543C3B-2D53-43F0-8587-1C5081B81574

P1476

Q38592404-32C1B1D6-D5F7-4521-AD16-629D0CF11747

P2093

Q38592404-31EBC50E-3753-4837-92F5-C9E059AFBAA7

Q38592404-6B4969B5-8D6C-45B1-9849-0D2FCFD4098E

Q38592404-7C35B9FA-61F9-4A08-BBBD-872896CAF525

P275

Q38592404-FEAB5669-9DF8-4A6F-83CF-DB2C6E8EED13

P2860

Q38592404-048A326F-D586-44C7-989F-63045936E2D1

Q38592404-0746F29B-133D-489F-B0BA-49ECD012BC8B

Q38592404-0916E723-00CE-4174-97B1-A139C8C80E1C

Q38592404-0B6D7E63-BCF4-41DF-B5B7-C05FE7716A79

Q38592404-0D629E82-EA6E-49DB-A099-CFADF3C1768C

Q38592404-0EA47B06-5937-46FF-8C94-59C1240DEE24

Q38592404-0FAB4DB1-ABC3-4F3B-8B4F-C1238130ACD1

Q38592404-12B73D51-93FF-4FF5-B88A-0E3DBD5723C7

Q38592404-13A22F0E-7172-4890-9C96-DCC1CAF6CD7B

Q38592404-149F431B-0EA4-46F9-8DE3-E3CABF1ED2C5

P304

Q38592404-B8D21808-BE14-45EB-96CA-19DA42DE29E0

P31

Q38592404-56B5639B-B530-4694-94A2-1BED388789A4

Q38592404-CBB8C3D0-E556-4FBA-950E-91218BB40CA8

P356

Q38592404-4760FE32-D580-4CF4-A343-DE9A12A4D6C6

P433

Q38592404-A598CBAA-6FD3-4CFC-BAA1-040302F5E759

P478

Q38592404-BC94E540-0204-411D-9E84-1A33F1F961DD

P577

Q38592404-BE380DAA-88C9-4E12-8EA1-2C33068C9B56

Q38592404-C28E05C2-25B0-4E84-BC97-ADAA6FDBDCA9

P5875

Q38592404-E2C3D2D9-2632-4AAC-A15E-F7C709B8DF02

P698

Q38592404-4E9B2753-AE65-4905-9EAF-8FE198312B04

P921

Q38592404-1D26B5C4-7DBB-4609-A20E-6861DCA73E04

Q38592404-417D78B2-51AF-44A2-8D3D-6E1D97DFF149

Q38592404-FFEDCAC0-DE91-43E1-98BB-D4BC302E7A9E

P932

Q38592404-51CAB9B6-4427-477D-905A-7E0C8D180C55

P356

P1433

Early Intervention in Psychiatry: the development, onset and treatment of emerging mental disorders

P1476

Clinical benefits and impact o ...... ipsychotics for schizophrenia.

@en

P2093

Gail Dawson

http://www.w3.org/2001/XMLSchema#string

Georgia L Stevens

http://www.w3.org/2001/XMLSchema#string

Jacqueline Zummo

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

A systematic review of the prevalence of schizophrenia.

Early intervention for psychosis

Antipsychotic medication for early episode schizophrenia

Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis

Is early intervention in psychosis cost-effective over the long term?

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

Shared decision making and medication management in the recovery process

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).

P304

365-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EIP.12278

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282277644

http://www.w3.org/2001/XMLSchema#string

P698

26403538

http://www.w3.org/2001/XMLSchema#string

P921

preventive health services

pharmaceutical preparation

P932

5054869

http://www.w3.org/2001/XMLSchema#string